What it is

Tesamorelin is a synthetic analog of growth hormone–releasing hormone (GHRH) designed to stimulate endogenous GH secretion. It is FDA-approved (as Egrifta / Egrifta SV) for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

Why people use it

Clinically, tesamorelin is used for its approved indication in HIV-associated lipodystrophy. Outside that context, it is sometimes sought for visceral fat reduction or “body recomposition,” but extrapolation beyond labeled populations should be cautious.

History and origin

Tesamorelin’s development reflects a targeted effort to address metabolic complications of HIV therapy and disease, particularly visceral adiposity. Its approval is grounded in controlled trials showing reductions in visceral adipose tissue, with labeling that reflects benefits and limitations.

How it works

By activating pituitary GHRH receptors, tesamorelin increases GH secretion and downstream IGF-1. The metabolic rationale is that GH signaling can influence lipolysis and fat distribution, with a measurable effect on visceral adipose tissue in the studied population.

Evidence landscape

Randomized trials in HIV-associated lipodystrophy demonstrate reductions in visceral adipose tissue and related imaging endpoints. Evidence for long-term outcomes such as cardiovascular events is more limited, and effects may diminish after discontinuation, highlighting that it is not a permanent “reset” of metabolism.

Safety reality

Tesamorelin has an FDA label and a defined adverse event profile, including injection-site reactions, elevations in IGF-1, and considerations around glucose metabolism and malignancy risk warnings/precautions reflected in prescribing information. Using non-pharmaceutical “tesamorelin” products introduces avoidable quality and safety uncertainties.

References

Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation: randomized placebo-controlled trial (2010). https://pubmed.ncbi.nlm.nih.gov/20101189/

Pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials (2010). https://pubmed.ncbi.nlm.nih.gov/20554713/

Egrifta (tesamorelin) for injection, prescribing information (FDA label PDF) (2010). https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022505s000lbl.pdf

TH9507 Extension Study in HIV-Associated Lipodystrophy (ClinicalTrials.gov). https://clinicaltrials.gov/study/NCT00608023